Kairos Pharma
KAPA
10 hedge funds and large institutions have $173K invested in Kairos Pharma in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
25% more funds holding
Funds holding: 8 → 10 (+2)
10.21% less ownership
Funds ownership: 11.51% → 1.3% (-10%)
88% less capital invested
Capital invested by funds: $1.46M → $173K (-$1.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$45.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$9.86K |
| 3 |
HF
HRT Financial
New York
|
+$9.63K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.85K |
| 5 |
Citigroup
New York
|
+$4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.31M |
| 2 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$45.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12.4K |
KAPA Hedge Fund Activity: Q2 2025 in Review
10 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q2 2025, worth a combined $173K — down 88% from $1.46M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KAPA positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $45.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.31M sold.
- 10 institutional investors held Kairos Pharma (KAPA) as of Q2 2025, up from 8 in Q1 2025.
- Funds reported $173K of Kairos Pharma stock for Q2 2025, down 88% quarter-over-quarter.
- 5 funds opened new Kairos Pharma positions in Q2 2025 and 3 closed out, a net change of +2 holders.
- The largest Kairos Pharma buyer in Q2 2025 was XTX Topco, an estimated $45.7K added.
- The largest Kairos Pharma seller in Q2 2025 was Armistice Capital, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2025.